NCT01524926 2023-12-11CREATEEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 2 Completed582 enrolled
NCT02465528 2019-12-27Ceritinib Rare Indications Study in ALK+ TumorsNovartisPhase 2 Terminated22 enrolled 16 charts